The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against LOOP Industries, Inc.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York captioned Tremblay v. Loop Industries, Inc., et al., (Case No. 1:20-cv-08538) on behalf of persons and entities that purchased or otherwise acquired Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) securities between September 24, 2018 and October 12, 2020, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who suffered a loss, click here to participate.

Loop is a technology company that purports to own proprietary technology that depolymerizes no- and low-waste PET plastic and polyester fiber. The resulting material is used to create PET resin for food-grade packaging.

On October 13, 2020, Hindenburg Research published a report alleging, among

Read More

The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Mesoblast Limited (MESO)

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Kristal v. Mesoblast Limited, et al., (Case No. 1:20-cv-08430), on behalf of persons and entities that purchased or otherwise acquired Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) securities between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”). Plaintiff pursues under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”)

If you are a shareholder who suffered a loss, click here to participate.

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial

Read More